386 related articles for article (PubMed ID: 27591143)
1. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.
Liu C; Cai D; Zhang L; Tang W; Yan R; Guo H; Chen X
Antiviral Res; 2016 Oct; 134():97-107. PubMed ID: 27591143
[TBL] [Abstract][Full Text] [Related]
2. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
3. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.
Cai D; Wang X; Yan R; Mao R; Liu Y; Ji C; Cuconati A; Guo H
Antiviral Res; 2016 Aug; 132():26-37. PubMed ID: 27185623
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
5. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
[TBL] [Abstract][Full Text] [Related]
6. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.
Ogura N; Watashi K; Noguchi T; Wakita T
Biochem Biophys Res Commun; 2014 Sep; 452(3):315-21. PubMed ID: 25150444
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.
He W; Li LX; Liao QJ; Liu CL; Chen XL
World J Gastroenterol; 2011 Mar; 17(11):1507-14. PubMed ID: 21472112
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
[TBL] [Abstract][Full Text] [Related]
9. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
10. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays.
Wu M; Li J; Yue L; Bai L; Li Y; Chen J; Zhang X; Yuan Z
Antiviral Res; 2018 Apr; 152():45-52. PubMed ID: 29432776
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays.
Zhou T; Guo H; Guo JT; Cuconati A; Mehta A; Block TM
Antiviral Res; 2006 Nov; 72(2):116-24. PubMed ID: 16780964
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of metachromin A on hepatitis B virus production via impairment of the viral promoter activity.
Yamashita A; Tamaki M; Kasai H; Tanaka T; Otoguro T; Ryo A; Maekawa S; Enomoto N; de Voogd NJ; Tanaka J; Moriishi K
Antiviral Res; 2017 Sep; 145():136-145. PubMed ID: 28827084
[TBL] [Abstract][Full Text] [Related]
13. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
14. An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.
Kim SY; Kim H; Kim SW; Lee NR; Yi CM; Heo J; Kim BJ; Kim NJ; Inn KS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559272
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus activities of Geranium carolinianum L. extracts and identification of the active components.
Li J; Huang H; Zhou W; Feng M; Zhou P
Biol Pharm Bull; 2008 Apr; 31(4):743-7. PubMed ID: 18379075
[TBL] [Abstract][Full Text] [Related]
16. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
Shi M; Sun WL; Hua YY; Han B; Shi L
PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.
Hofmann S; Luther J; Plank V; Oswald A; Mai J; Simons I; Miller J; Falcone V; Hansen-Palmus L; Hengel H; Nassal M; Protzer U; Schreiner S
Microbiol Spectr; 2024 May; 12(5):e0378823. PubMed ID: 38567974
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
19. Control of cccDNA function in hepatitis B virus infection.
Levrero M; Pollicino T; Petersen J; Belloni L; Raimondo G; Dandri M
J Hepatol; 2009 Sep; 51(3):581-92. PubMed ID: 19616338
[TBL] [Abstract][Full Text] [Related]
20. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
